Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [978]

How to avoid false positives in lung cancer

Dr Claudia Henschke - Mount Sinai Hospital, New York, USA

How to avoid false positives in lung cancer ( Dr Claudia Henschke - Mount Sinai Hospital, New York, USA )

Current state of the art radiotherapy in lung cancer

Prof Corinne Faivre-Finn - The Christie NHS Foundation Trust, Manchester, UK

Current state of the art radiotherapy in lung cancer ( Prof Corinne Faivre-Finn - The Christie NHS Foundation Trust, Manchester, UK )

Maintenance in NSCLC

Dr Benjamin Besse - Institut Gustave Roussy, Paris, France

Maintenance in NSCLC ( Dr Benjamin Besse - Institut Gustave Roussy, Paris, France )

Recent advances and emerging therapies in lung cancer

Prof McVie, Prof Dive, Dr Nicolson and Prof Seckl

Recent advances and emerging therapies in lung cancer ( Prof McVie, Prof Dive, Dr Nicolson and Prof Seckl )

Editor's Choice for August 2016

Prof Gordon McVie - Editor in Chief, ecancer

Editor's Choice for August 2016 ( Prof Gordon McVie - Editor in Chief, ecancer )

Survivor perspectives of ALK lung cancer

Matthew Hiznay - Cleveland, Ohio, USA

Survivor perspectives of ALK lung cancer ( Matthew Hiznay - Cleveland, Ohio, USA )

Lung cancer immunotherapy

Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA

Lung cancer immunotherapy ( Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA )

'Other' targets in lung cancer

Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA

'Other' targets in lung cancer ( Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA )

Editor's Choice for July 2016

Prof Gordon McVie - Editor in Chief, ecancer

Editor's Choice for July 2016 ( Prof Gordon McVie - Editor in Chief, ecancer )

The steady progress of targeted therapies

Dr Anton Berns - Netherlands Cancer Institute, Amsterdam, Netherlands

The steady progress of targeted therapies ( Dr Anton Berns - Netherlands Cancer Institute, Amsterdam, Netherlands )

Prof Michael Seckl: Why attend Future Horizons in Lung Cancer?

Prof Michael Seckl - Imperial College London, London

Prof Michael Seckl: Why attend Future Horizons in Lung Cancer? ( Prof Michael Seckl - Imperial College London, London )

Polycomb repressors and epigenetic therapy

Dr Maarten van Lohuizen - Netherlands Cancer Institute, Netherlands, UK

Polycomb repressors and epigenetic therapy ( Dr Maarten van Lohuizen - Netherlands Cancer Institute, Netherlands, UK )

More from ecancer